Tobramycin disposition in ICU patients receiving a once daily regimen: Population approach and dosage simulations

British Journal of Clinical Pharmacology

Volumn 71, Issue 1, 2011, Pages 61-71

  Conil, Jean Marie ^a,b   Georges, Bernard ^a,b   Ruiz, Stéphanie ^a   Rival, Thomas ^a   Seguin, Thierry ^a   Cougot, Pierre ^a   Fourcade, Olivier ^a,b   Pharmd, Georges Houin ^c   Saivin, Sylvie ^b,c  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Institut Federatif de Biologie   (France)

Author keywords

ICU patients; Population pharmacokinetics; Tobramycin

Indexed keywords

CEFTAZIDIME; IMIPENEM; TOBRAMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; CLINICAL ARTICLE; COMPARTMENT MODEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; MALE; MONTE CARLO METHOD; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CREATININE; FEMALE; HUMANS; INTENSIVE CARE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOBRAMYCIN;

EID: 78649995402     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03793.x     Document Type: Article

References (61)

1. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27: (Suppl. C): 29-40.
2. Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28: 753-64.
3. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-5.
4. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312: 338-45.
5. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
6. Moore RD, Smith CR, Lietman PS. Predicting aminoglycoside nephrotoxicity. Jama 1986; 256: 864-6.
7. Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis 2005; 52: 123-7.
8. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605-9.
9. Hennig S, Norris R, Kirkpatrick CM. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis - a population pharmacokinetic study. Br J Clin Pharmacol 2008; 65: 502-10.
10. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840-51; quiz 859.
11. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 623-9.
12. Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 1986; 5: 319-24.
13. Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994; 38: 1165-8.
14. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549-55.
15. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39: 677-86.
16. Reeves DS, MacGowan AP. Once-daily aminoglycoside dosing. Lancet 1993; 341: 895-6.
17. Ter Braak EW, De Vries PJ, Bouter KP, Van Der Vegt SG, Dorrestein GC, Nortier JW, Van Dijk A, Verkooyen RP, Verbrugh HA. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58-66.
18. Parker SE, Davey PG. Practicalities of once-daily aminoglycoside dosing. J Antimicrob Chemother 1993; 31: 4-8.
19. Beaucaire G, Leroy O, Beuscart C, Karp P, Chidiac C, Caillaux M. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 1991; 27: (Suppl. C): 91-103.
20. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786-95.
21. Barletta JF, Johnson SB, Nix DE, Nix LC, Erstad BL. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma 2000; 49: 869-72.
22. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002; 28: 936-42.
23. Dorman T, Swoboda S, Zarfeshenfard F, Trentler B, Lipsett PA. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group. Surgery 1998; 124: 73-8.
24. Peris-Marti JF, Borras-Blasco J, Rosique-Robles JD, Gonzalez-Delgado M. Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation. J Clin Pharm Ther 2004; 29: 65-70.
25. Bracco D, Landry C, Dubois MJ, Eggimann P. Pharmacokinetic variability of extended interval tobramycin in burn patients. Burns 2008; 34: 791-6.
26. Beckhouse MJ, Whyte IM, Byth PL, Napier JC, Smith AJ. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care 1988; 16: 418-22.
27. Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16: 327-30.
28. Mann HJ, Fuhs DW, Awang R, Ndemo FA, Cerra FB. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharm 1987; 6: 148-53.
29. Niemiec PW Jr, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg 1987; 122: 207-12.
30. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004; 30: 2145-56.
31. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30: 674-81.
32. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990; 212: 581-91.
33. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Reller LB. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24: 584-602.
34. Devine B. Gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650-5.
35. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9.
36. Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999; 37: 1-16.
37. Li RC. New pharmacodynamic parameters for antimicrobial agents. Int J Antimicrob Agents 2000; 13: 229-35.
38. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7: 589-96.
39. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
40. Robert S, Zarowitz BJ, Peterson EL, Dumler F. Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med 1993; 21: 1487-95.
41. Ang DN, Armen SB, Armstrong J, Bihorac A, Caruso LJ, Elamin EM, Freeman R, Gabrielli A, Gallagher TJ, Layon AJ. Infectious disease. In: Handbook of Critical Care, eds Martin LC, Naik B, Peters CW, Yingling JM. Gainesville, FL: Shands Hospital at the University of Florida: Division of Critical Care Medicine, Department of Anesthesiology, University of Florida College of Medicine 2008; 59-60.
42. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982; 8: 195-222.
43. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-66.
44. Bignardi GE, Riley U. Once-daily aminoglycoside dosing. Lancet 1993; 341: 894-5.
45. Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target concentration intervention - parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 2004; 58: 8-19.
46. Inclan G, Suarez E, Calvo R, Aguirre C, Macheras P, Gazouli M, Lukas JC. Bicompartmental kinetics of tobramycin analysed with a wide range of covariates. Int J Antimicrob Agents 2005; 26: 304-11.
47. Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother 2002; 50: 553-9.
48. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
49. Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47: 637-43.
50. Xuan D, Lu JF, Nicolau DP, Nightingale CH. Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen. Int J Antimicrob Agents 2000; 15: 185-91.
51. Green TP, Mirkin BL, Peterson PK, Sinaiko AR, Ramsay NK, O'Dea RF. Tobramycin serum level monitoring in young patients with normal renal function. Clin Pharmacokinet 1984; 9: 457-68.
52. Bourguignon L, Goutelle S, Gerard C, Guillermet A, Burdin de Saint Martin J, Maire P, Ducher M. [Amikacin pharmacokinetics in adults: a variability that questions the dose calculation based on weight]. Therapie 2009; 64: 47-53.
53. Conil JM, Georges B, Breden A, Segonds C, Lavit M, Seguin T, Coley N, Samii K, Chabanon G, Houin G, Saivin S. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents 2006; 28: 226-30.
54. Conil JM, Georges B, Lavit M, Laguerre J, Samii K, Houin G, Saivin S. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br J Clin Pharmacol 2007; 64: 27-35.
55. Georges B, Conil JM, Seguin T, Ruiz S, Minville V, Cougot P, Decun JF, Gonzalez H, Houin G, Fourcade O, Saivin S. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation and reason for admission. Antimicrob Agents Chemother 2009.
56. Garraffo R. Signification clinique des corrélations pharmacocinétique/pharmacodynamie des antibiotiques chez les patients de réanimation. Réanimation 2005; 14: 264-75.
57. Martin C, Mallet MN, Saux P, Bruguerolle B, Herat V, Gouin F. Tobramycin dosing in mechanically ventilated patients. Inaccuracy of a 'rule of thumb'. J Antimicrob Chemother 1988; 22: 505-11.
58. Triginer C, Izquierdo I, Fernandez R, Torrent J, Benito S, Net A, Jane F. Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation. Eur J Clin Pharmacol 1991; 40: 297-302.
59. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999; 44: 319-27.
60. Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993; 21: 172-3.
61. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45: 753-60.